ad image

Company Info

AbbVie

AbbVie

Drug Discovery & Development

Overview

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on TwitterFacebook, Instagram, YouTube and LinkedIn.
AbbVie
Contributions
38 Contributions1 / 2
AbbVie
Announcement

AbbVie Announces Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie

PR-12-24-NI-134Dec 11, 2024
AbbVie
Financing

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

AbbVie

PR-10-24-NI-65Oct 29, 2024
AbbVie
Clinical Trials

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie

PR-09-24-NI-17Sep 26, 2024
AbbVie
Drug Update

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.

AbbVie

PR-M07-21-011Jul 22, 2021
AbbVie
M&A

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

AbbVie

PR-M07-21-01Jul 06, 2021
AbbVie

Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

AbbVie

PR-M05-21-008-993May 12, 2021
AbbVie
Partnership

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie

PR-M09-20-NI-06Sep 04, 2020
AbbVie
M&A

AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan

AbbVie

PR-M05-20-NI-012-1566May 08, 2020
AbbVie
Business

AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition

AbbVie

PR-M01-20-NI-016Jan 09, 2020
AbbVie
Collaboration

AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics

AbbVie

PR-M12-19-NI-021Dec 12, 2019
AbbVie
FDA Approval

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis

AbbVie

PR-M08-19-NI-073Aug 26, 2019
AbbVie
M&A

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

AbbVie

PR-M07-19-NI-038Jul 16, 2019
AbbVie
M&A

AbbVie to Acquire Allergan for $63 Billion

AbbVie

PR-M06-19-NI-052Jun 25, 2019
AbbVie
Announcement

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

AbbVie

PR-M05-19-NI-054May 20, 2019
AbbVie
Legal

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

AbbVie

PR-M05-19-NI-056May 20, 2019
AbbVie
Donation

AbbVie Donates $40 Million to Rebuild North Chicago Middle School

AbbVie

PR-M03-19-NI-066Mar 25, 2019
AbbVie
Pancreatic Cancer

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

AbbVie

PR-M01-19-NI-061Jan 22, 2019
AbbVie
Leadership

AbbVie Announces Executive Leadership Changes

AbbVie

PR-M01-19-NI-003Jan 02, 2019
AbbVie
Oncology

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR

AbbVie

PR-M12-18-NI-017Dec 06, 2018
AbbVie
Drug Development

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

AbbVie

PR-M11-18-NI-053Nov 15, 2018
1 / 2
0 Contributors1 / 0

No authors found

1 / 0